CSC
PRLD icon

Caldwell Sutter Capital’s Prelude Therapeutics PRLD Stock Holding History

Caldwell Sutter Capital’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,000
Closed -$3.42K – 944
2026
Q1 		$3.42K Sell
1,000
-1,000
-50% -$2.62K ﹤0.01% 697
2025
Q4 		$5.8K Buy
+2,000
New +$3.38K ﹤0.01% 616

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Caldwell Sutter Capital's PRLD Position: Q2 2026 in Review

Caldwell Sutter Capital sold out of Prelude Therapeutics (PRLD) in Q2 2026, closing a stake of 1,000 shares — an estimated $3.42K sold.

Caldwell Sutter Capital first reported a position in PRLD in Q4 2025 and held it in 2 quarters. The position peaked at $5.8K in Q4 2025. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Caldwell Sutter Capital reported no remaining Prelude Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Caldwell Sutter Capital sold 1,000 Prelude Therapeutics shares in Q2 2026, an estimated $3.42K.
  • Caldwell Sutter Capital first reported a position in Prelude Therapeutics in Q4 2025 and held it in 2 quarters.
  • Caldwell Sutter Capital's Prelude Therapeutics position peaked at $5.8K in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Caldwell Sutter Capital's 13F filing for Q2 2026, filed 5 Aug 2026.